DUBLIN--(BUSINESS WIRE)--The "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan" report has been added to ResearchAndMarkets.com's offering.
Japanese Pharmaceutical Market Value Edging Towards $80 Billion by 2020
This report provides information on the healthcare, regulatory, and reimbursement landscape in Japan. It includes annualized data on the pharmaceutical and medical device sectors from 2013 and forecast to 2020, plus an analysis of key market drivers and barriers.
The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Japan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Japan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by a team of industry experts.
Japan's pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the healthcare burden of the country's aging population, according to research and consulting firm The authors.
However, the company's latest report* states that the Japanese government's promotion of generic drugs, its biennial pricing review system and the depreciation of the yen against the dollar will be limiting factors in what is the second largest mature pharmaceutical market in the world by value.
The market was valued at $64.2 billion in 2008 and peaked at $88 billion in 2011, before a slight dip to $87.2 billion in 2012. A substantial drop in 2013 saw its value decrease by over $14 billion, but The authors expects a steady period of recovery to follow.
Joshua Owide, The authors's Director of Healthcare Industry Dynamics, says: Deregulation measures introduced in April 2005 have had an impact on overall market performance and more efficient drug reviews have facilitated the entry of new products.
The approval process has now caught up with that outside of Japan, as highlighted by two approvals for Bristol-Myers Squibb, the Daklinza (daclatasvir) and Sunvepra (asunaprevir) dual regimen for hepatitis C, and Opdivo (nivolumab) for melanoma, prior to their approval by the US Food and Drug Administration.
Aside from wider economic factors, such as currency exchange rates, The authors states that increased use of generic drugs will be a key contributor to the forthcoming period of slow growth to 2020.
Owide continues: In 2008, generics accounted for 19% of the pharmaceutical space in terms of volume, rising to 25.2% in 2013. Japan has set a goal for generics to account for 60% of all drug use by 2017.
To this end, the Ministry of Health, Labor and Welfare announced new price cuts in 2013 for drugs with generic replacement of less than 60%, a move which is likely to limit future growth in the pharmaceutical arena.
Key Topics Covered:
- Executive Summary
- Overview of Pharmaceutical Market
- Overview of Medical Device Market
- Deals Analysis
- Porter's Five Forces Model
- Market Access
- Country Healthcare Landscape
- Opportunities and Challenges
-
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/t6wxot
